| 16.79 -1.17 (-6.51%) | 08-28 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 21.34 |
1-year : | 22.54 |
| Resists | First : | 18.27 |
Second : | 19.29 |
| Pivot price | 18.06 |
|||
| Supports | First : | 16.62 |
Second : | 13.83 |
| MAs | MA(5) : | 17.73 |
MA(20) : | 18.16 |
| MA(100) : | 16.1  |
MA(250) : | 13.02 |
|
| MACD | MACD : | -0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 24.7 |
D(3) : | 31.6 |
| RSI | RSI(14): 37.9 |
|||
| 52-week | High : | 20.21 | Low : | 6.92 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ TRVI ] has closed below the lower bollinger band by 16.4%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 33.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 18.11 - 18.2 | 18.2 - 18.29 |
| Low: | 16.38 - 16.48 | 16.48 - 16.59 |
| Close: | 16.6 - 16.76 | 16.76 - 16.93 |
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.
Wed, 26 Aug 2026
Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026 - GlobeNewswire
Thu, 20 Aug 2026
Trevi Therapeutics (TRVI) Institutional Ownership 2026 $TRVI - MarketBeat
Thu, 20 Aug 2026
Trevi Therapeutics: A Specialty Beachhead Creates A Chronic Cough Platform (NASDAQ:TRVI) - Seeking Alpha
Fri, 14 Aug 2026
Does Wider Losses And New US$149.2m Shelf Offering Change The Bull Case For Trevi (TRVI)? - simplywall.st
Thu, 06 Aug 2026
Trevi starts a chronic-cough trial for ~2–3M U.S. patients - Stock Titan
Fri, 17 Jul 2026
Trevi Therapeutics (TRVI) Soars as Haduvio Taps Into $15B Addressable Market - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 142 (M) |
| Shares Float | 118 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 107.6 (%) |
| Shares Short | 13,150 (K) |
| Shares Short P.Month | 13,870 (K) |
| EPS | -0.35 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.25 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -13.9 % |
| Return on Equity (ttm) | -19.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.42 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -53 (M) |
| Levered Free Cash Flow | -33 (M) |
| PE Ratio | -47.98 |
| PEG Ratio | 0 |
| Price to Book value | 7.42 |
| Price to Sales | 0 |
| Price to Cash Flow | -45.46 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|